徐栋生 1,万爱妮 1,陈蕴 1,何杨 2,杨建峰 3,金坚 1
XU Dong-sheng1, WAN Ai-ni1, CHEN Yun1, HE Yang2, YANG Jian-feng3, JIN Jian1
1. Laboratory of Drug Design and Molecular Pharmacology, School of Pharmaceutical Science, Jiangnan University, Wuxi 214122, China; 2. Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China; 3. Cyrus Tang Hematology Center and Ministry of Education Engineering Center of Hematological Disease, Soochow University, Suzhou 215123, China
摘要:
肝纤维化是常见的慢性进行性肝病,是肝脏细胞在一种或多种病因长期或反复作用下进行应激反应的过程。肝纤维化过程中,胞外基质大量累积形成瘢痕组织,引起肝脏功能减退或衰竭,严重危害生命健康。多个独立的研究证明,干细胞治疗促进肝纤维化恢复。干细胞治疗过程中,干细胞迁移至肝损伤部位,通过旁分泌途径改善纤维化瘢痕区域的微环境,延缓纤维化进程。该文从肝纤维化形成过程、肝纤维化治疗和干细胞疗法三方面进行综述。